Fetuin-A could serve as new molecular target in the elucidation of complex pathophysiological pathways involved in the onset of metabolic disorders, and could also be used as a useful marker in clinical practice in the future for the early diagnosis of these conditions. Also provides a rationale for evaluating circulating fetuin-A to see if it could affect the pathophysiological process of the risk of various metabolic disorders. Specifically, this evaluation might lead to new perspectives in the early diagnosis, identification of novel biomarkers, and discovery of novel targets for pharmacological in the future.